---

🩺 Volatile Anaesthetic Agents & Vaporizers

Q&A — Anaesthesia Perspective

Based on Miller's Anesthesia, 2-Volume Set, 10th Edition

---

SECTION 1: VOLATILE ANAESTHETIC AGENTS — FUNDAMENTALS

---

— Miller's Anesthesia 10e, p. 2273–2274

---

— Miller's Anesthesia 10e, pp. 2270, 2299

---

• Halothane — on the WHO Essential Medicines List; widely used in LMICs due to cost (250 mL ~$21 in Uganda vs. sevoflurane ~$250)
• Isoflurane — on the WHO Essential Medicines List
• Sevoflurane — added to the WHO Essential Medicines List in 2023
• Ether — removed from the WHO Essential Medicines List

— Miller's Anesthesia 10e, p. 267

---

1. GABA-A receptor potentiation — Ether anaesthetics (isoflurane, sevoflurane, desflurane) and halothane all enhance GABA-A receptor function. GABA-A receptors are the principal inhibitory Cl⁻ channels in the neocortex. Channel opening drives the membrane potential toward the Cl⁻ equilibrium potential, producing neuronal inhibition.
2. Glycine receptor potentiation — GlyRs are the dominant inhibitory channels in the spinal cord and are also enhanced by volatiles.
3. NMDA-type glutamate receptor inhibition — Reduction of excitatory neurotransmission.
4. K⁺ channel enhancement (K2P "leak" channels) — Maintain resting membrane potential; positively modulated by volatiles (e.g. a sevoflurane binding site has been identified in the Kq1.2 channel).
5. Voltage-gated Na⁺ and Ca²⁺ channel inhibition — Additional mechanisms.

The binding site on GABA-A receptors is located in the outer third of the transmembrane domain between the α and β subunits. — Miller's Anesthesia 10e, pp. 1836–1837

---

• CMR suppression: All volatiles reduce CMR in a dose-dependent fashion (similar to IV agents).
• Direct cerebral vasodilation: Direct effect on vascular smooth muscle → increases CBF.

— Miller's Anesthesia 10e, pp. 1004–1007

---

• All volatile agents except desflurane reduce airway resistance.
• Sevoflurane > isoflurane > halothane in bronchodilator potency (though for treating status asthmaticus, all three appear clinically similar).
• Desflurane does NOT bronchodilate and may cause airway irritability — it is not recommended for inhalational induction or patients with reactive airways.
• The ceiling effect means low concentrations of volatiles significantly reduce upper airway resistance; increasing concentration does not further reduce resistance in distal airways/alveoli (which lack smooth muscle).

• Volatiles cause a rightward shift of the apneic threshold (the minimum PaCO₂ required to initiate spontaneous respiration) → they blunt ventilatory response to hypercapnia.
• In spontaneously breathing anaesthetized patients, the ventilatory response to expiratory resistance is disproportionately blunted (important in COPD, asthma, hypopharyngeal obstruction).

Clinical pearl: Sevoflurane is the preferred agent for inhalational induction (pleasant odour, non-irritant airways). Desflurane is avoided for induction. — Miller's Anesthesia 10e, pp. 2075–2077

---

• MAC 0.75% (potent), blood:gas coefficient 2.4 → slower onset and offset than modern agents
• Sweet smelling → useful for inhalational induction
• Cardiac depressant and arrhythmogenic — especially in the presence of elevated ETCO₂
• Practical tip: Once IV access is secured after inhalational induction with halothane, rapidly reduce the inspired concentration to minimise cardiac depression
• Halothane hepatitis (rare immune-mediated hepatotoxicity) is a significant concern

— Miller's Anesthesia 10e, pp. 267–268

---

SECTION 2: VAPORIZERS

---

• Out-of-circuit (virtually all modern vaporizers): Output is introduced into the circuit via a fresh gas line
• In-circuit (draw-over systems): Used in resource-constrained environments and for ICU sedation

• Variable bypass vaporizer (e.g., GE Tec 7, Dräger Vapor 2000) — most common
• Dual-circuit vaporizer (Tec 6 for desflurane)
• Cassette vaporizer (e.g., Aladin cassette)
• Injection vaporizer

— Miller's Anesthesia 10e, p. 2278

---

1. Fresh gas flow (FGF) enters the vaporizer
2. The concentration control dial splits flow into:
   • Bypass chamber — carries undiluted fresh gas
   • Vaporizing chamber — gas passes over wicks/baffles (increased surface area), becomes saturated with anaesthetic vapour
3. The two streams recombine at the outlet at the desired concentration
4. A temperature-compensating device (bimetallic strip) automatically adjusts the splitting ratio to maintain constant output as temperature changes:
   • Cooler → strip diverts more flow through vaporizing chamber
   • Warmer → strip allows more flow through bypass

— Miller's Anesthesia 10e, pp. 2279–2281, 2291

---

1. Excessive bypass flow required: Desflurane's SVP is 669 mmHg at 20°C. 100 mL/min through the vaporizing chamber would entrain 735 mL/min of desflurane (88% concentration). To dilute this to 6% (1 MAC), you would need ~12 L/min of bypass flow — clinically prohibitive.
2. Excessive evaporative cooling: Because MAC for desflurane is ~6% (much higher than other agents), large volumes must be vaporized per unit time. This would cause uncontrollable cooling of the liquid, reducing output unpredictably.
3. Risk of boiling: Desflurane's boiling point is 22.8°C (73°F) — at the upper end of normal operating room temperatures. If it were to boil in a variable bypass vaporizer, output would be uncontrollable and potentially lethal.

— Miller's Anesthesia 10e, pp. 2299–2300

---

• The desflurane sump is heated to 39°C, generating a desflurane vapour reservoir at 1300 mmHg
• Two independent, parallel gas circuits:
  • Fresh gas circuit (orange): FGF enters, passes through a fixed restrictor (R1), exits at the outlet
  • Vapour circuit (blue): Desflurane vapour from the heated sump passes through a pressure-regulating valve (downregulated to match FGF circuit pressure), then through a variable restrictor (R2) — the concentration control dial
• The shut-off valve is either fully closed (dial off) or fully open (dial on)
• The two streams combine at the outlet

— Miller's Anesthesia 10e, pp. 2300–2301

---

• As ambient temperature increases, vaporizer output slightly exceeds the dial setting (especially at higher settings)
• Example: At an 8% sevoflurane dial setting, output approaches ~10% at 35°C — nearly 25% more than the intended concentration

— Miller's Anesthesia 10e, p. 2291

---

• Initial decrease (seconds): N₂O is more soluble than O₂ in liquid anaesthetic → more N₂O dissolves, reducing the volume exiting the vaporizing chamber
• New lower steady state (after ~1 minute): Differences in density and viscosity of N₂O vs. O₂ alter the relative gas flows through bypass and vaporizing channels

— Miller's Anesthesia 10e, pp. 2292–2294

---

• Designs vary between manufacturers
• Interlock devices are not immune from failure — anaesthetic overdose can result from interlock failure
• After changing or adding a vaporizer, always ensure it is properly seated and locked, then perform a vaporizer leak test as required by the manufacturer
• Detachable mounting systems can cause low-pressure leaks or fresh gas obstruction if connection fails

— Miller's Anesthesia 10e, pp. 2261–2262

---

• Example: V_circ = 6 L, FGF = 6 L/min → τ = 1 minute
• After 1 time constant: 63.1% of the old gas is replaced
• After 3 time constants: ~95% wash-in achieved

• High FGF → faster wash-in → faster change in inspired concentration
• Low FGF → slower wash-in → more economical use of agent but slower to change depth
• The difference between delivered partial pressure (P_del) and circuit partial pressure (P_circ) determines direction and magnitude of net anaesthetic gas flow. To remove agent from the circuit, P_del must be less than P_circ.

— Miller's Anesthesia 10e, pp. 1932–1933

---

SECTION 3: HIGH-YIELD CLINICAL PEARLS

---

---

SECTION 4: ENVIRONMENTAL NOTE

— Miller's Anesthesia 10e, p. 2075 (block6, line 146)

---

---

Topics Covered (16 Q&As):

• MAC definition and clinical relevance
• Physical properties comparison table (halothane, isoflurane, sevoflurane, desflurane)
• WHO Essential Medicines List status
• Molecular mechanism of action (GABA-A, glycine, NMDA, K2P channels)
• CNS effects — CBF/CMR dose-response relationship, ICP, autoregulation
• Respiratory effects — bronchodilation, ventilatory drive, airway irritability
• Halothane in resource-limited settings

• Classification (in-circuit vs. out-of-circuit; variable bypass, dual-circuit, cassette, injection)
• Variable bypass vaporizer mechanism (splitting ratio, wicks, temperature compensation)
• Why desflurane cannot be used in variable bypass vaporizers (3 reasons)
• Tec 6 desflurane vaporizer operating principles
• Temperature effect on vaporizer output
• Carrier gas composition effects (O₂ vs. N₂O)
• Vaporizer interlock system safety
• Fresh gas wash-in mathematics (time constant)
• Environmental impact

🫁 Inhalational Agents — Extended Q&A

Miller's Anesthesia 10e | Barash Clinical Anesthesia 9e | Morgan & Mikhail 7e

Sources are cited after each answer as [Miller], [Barash], or [Morgan]

---

SECTION A: PHARMACOKINETICS — UPTAKE & DISTRIBUTION

---

1. Alveolar ventilation (V̇alv) — Increased ventilation delivers more anaesthetic from the circuit to the alveoli, accelerating the rise of Palv. This is why hyperventilation speeds induction.
2. Cardiac output (Q̇) — Increased cardiac output removes more anaesthetic from alveolar gas into pulmonary blood, thereby slowing the rise of Palv. Clinically: when ETCO₂ drops and end-tidal anaesthetic concentration rises unexpectedly, suspect a fall in cardiac output.
3. Blood:gas partition coefficient (λb/g) — The higher the solubility, the greater the capacity of blood to absorb anaesthetic from alveoli, slowing the rise of Palv. Agents with high solubility (halothane, λ = 2.4) equilibrate slowly; agents with low solubility (desflurane, λ = 0.45) equilibrate rapidly.

The mathematical relationship: dPalv/dt = (V̇alv / Valv) × (Pcirc − Palv) − (Q̇ × λb/g / Valv) × (Palv − Pmv) — [Miller], pp. 1940–1944

---

• Initiate with moderate-to-high FGF (≥6 L/min) and Pdel = 2 × MAC-immobility
• Once Palv reaches or slightly exceeds target, reduce Pdel
• Slowly decrease Pdel and FGF as the inspired-to-expired anaesthetic gradient narrows

— [Miller], pp. 1957–1959

---

• Alveolar side: Less anaesthetic is extracted from alveoli → Palv rises faster (shunted blood cannot take up anaesthetic)
• Arterial side: Part = mixture of well-equilibrated pulmonary venous blood + shunted venous blood at low Pmv → Part lags behind Palv

• For insoluble agents (N₂O, desflurane): The shunt effect on Part/Palv is large — induction is noticeably slowed despite rapid Palv rise, because the CNS sees arterial blood, not alveolar gas
• For soluble agents (halothane): The shunt effect on Part/Palv is smaller — blood has high capacity to carry agent, so Part tracks Palv more closely

— [Miller], pp. 1944–1945

---

• At Q̇ = 5 L/min, initial N₂O uptake ≈ 1550 mL/min
• If 50% of N₂O is rapidly absorbed, the remaining alveolar gas is concentrated — alveolar N₂O falls only 24% (not 50%)
• Simultaneously, alveolar Piso and PO₂ both rise above inspired values — this is the second gas effect

— [Miller], pp. 1946–1947

---

• Increased dead space reduces effective alveolar ventilation, slowing anaesthetic delivery to blood
• This effect is most pronounced for low-solubility agents at high FGF (where alveolar ventilation is the rate-limiting factor)
• For high-solubility agents at low FGF: increased dead space reduces initial uptake, which conserves Pcirc and creates a compensatory rise in Palv — partially self-correcting

— [Miller], p. 1940

---

SECTION B: MAC — MODIFIERS & VARIANTS

---

— [Miller], pp. 1957–1958

---

— [Morgan], Ch. 8; [Miller], pp. 2273–2274

---

• They are not dependent on the kidneys for elimination
• They have minimal direct effects on renal blood flow

— [Morgan], pp. 1238–1239 (Ch. 30)

---

SECTION C: CARDIOVASCULAR EFFECTS

---

• Desflurane: Rapid concentration increases (>1 MAC within 1 minute) cause marked sympathetic activation — tachycardia and hypertension — mediated by direct airway irritation and SNS discharge. This is not seen with sevoflurane or isoflurane at comparable rates of increase.
• Halothane sensitises the myocardium to catecholamine-induced arrhythmias — avoid adrenaline infiltration with halothane (limit to 1:100,000, max ~1 μg/kg)
• Isoflurane controversy: Early concern about "coronary steal" — vasodilation of non-stenosed vessels diverting blood from stenosed territory. Now considered not clinically significant at 1 MAC with adequate diastolic pressure

---

• Activation of mitochondrial K_ATP channels and protein kinase C pathways
• Reduction in mitochondrial permeability transition pore opening during reperfusion
• Decreased cardiomyocyte apoptosis

— [Miller], p. 2274 context; [Barash], Ch. 22 context

---

SECTION D: RESPIRATORY EFFECTS

---

• Volatiles cause a rightward shift of the CO₂ response curve (increased apnoeic threshold) — spontaneous breathing ceases if mechanical ventilation drives PaCO₂ below threshold
• At >1 MAC, the peripheral chemoreceptor component of the CO₂ response is abolished; only the central loop remains
• In spontaneously breathing patients under volatiles → hypoventilation and hypercapnia are expected without ventilatory support

• Abolished at ≈1.1 MAC of any volatile agent
• 0.1 MAC (subanesthetic concentration) profoundly attenuates HVR — even without opioids
• Potency of HVR suppression: halothane > enflurane > sevoflurane > isoflurane > desflurane

• Premature infants — risk of postoperative apnoea
• OSA patients — already impaired HVR; volatile residuals worsen this significantly
• High altitude workers and climbers — HVR is their primary defence against hypoxia

— [Miller], pp. 2137–2138

---

• All volatile agents dilate the pulmonary vasculature — they reduce HPV
• However, the effect is modest in normal lungs — the small ↓PVR is usually offset by the concomitant reduction in cardiac output, with minimal net change in PAP
• In clinical concentrations (1 MAC): approximately 20% inhibition of HPV with isoflurane → ~4% increase in intrapulmonary shunt fraction (ΔQ̇s/Q̇t)

• Sevoflurane and desflurane have been shown to preserve HPV in chronically instrumented dog models (see Fig. 19.13, Miller's — PAP-LAP vs. left pulmonary flow was unchanged from conscious state)
• Multiple clinical studies comparing isoflurane, sevoflurane, desflurane vs. propofol TIVA during OLV show no clinically significant differences in shunt fraction or arterial oxygenation
• When anaesthetic depth is matched by BIS, propofol and sevoflurane produce comparable reductions in PaO₂ during OLV

— [Miller], pp. 2105–2116

---

• Act via GABA-A agonism + K⁺ channel activation + NMDA antagonism
• EEG shows: Loss of high-frequency (>20 Hz) power → emergence of narrowband delta (~3 Hz), theta (~8 Hz), and alpha (~11 Hz) oscillations — reflecting thalamocortical hyperpolarisation
• As concentration increases above ~1.7%: alpha peak slows from ~10 Hz to <8 Hz (below traditional alpha band) → shift from alpha to delta dominance = deeply hyperpolarised thalamocortical system
• At high concentrations: burst suppression
• Sevoflurane and enflurane generate more sharp waves (epileptiform spikes) than desflurane or isoflurane, especially with hypocapnia, high concentration, and absence of N₂O/opioids

• Propofol produces broadly similar EEG pattern but narrowband alpha/delta oscillations are more pronounced
• Alpha peak frequency does not slow below 10 Hz with propofol (unlike volatiles)
• Theta peak is less common with propofol

— [Miller], pp. 5385–5387

---

SECTION E: ORGAN-SPECIFIC EFFECTS

---

• Halothane undergoes ~20% oxidative metabolism by CYP2E1 → generates trifluoroacetyl (TFA) intermediates
• TFA binds to hepatic microsomal proteins → acts as a hapten → triggers an immune-mediated reaction (Type IV hypersensitivity)
• The result is immune-mediated hepatocellular necrosis (halothane hepatitis)
• Two forms: mild (transient ↑transaminases, 20–30% incidence after halothane) and fulminant (1:10,000–30,000, high mortality)
• Risk factors: repeated exposures, middle-aged obese females, prior halothane reaction

• Sevoflurane is the safest volatile for patients with liver disease or prior halothane reactions — it does not produce TFA metabolites or fluoroacetylated liver proteins
• A patient sensitised to any halogenated agent who then develops hepatic injury should not receive any other fluorinated anaesthetic — cross-sensitisation is possible
• Even desflurane (0.02% metabolism) has been implicated in hepatotoxicity in a patient previously sensitised by halothane

— [Barash], pp. 3961–3962

---

• All volatile agents (halothane, isoflurane, sevoflurane, desflurane) decrease renal vascular resistance
• They are not renally eliminated → dose adjustment is not required in CKD
• They are generally safe in mild-to-moderate renal impairment

• Sevoflurane reacts with CO₂ absorbents (especially Baralyme) to produce Compound A (pentafluoroisopropenyl fluoromethyl ether)
• In laboratory rats: Compound A causes dose-dependent proximal tubular necrosis (Frank renal injury)
• In humans: No clinical study has detected kidney injury attributable to Compound A — the threshold for nephrotoxicity in rats appears to be considerably higher than concentrations encountered clinically
• Precautionary recommendation (some authorities): Use FGF ≥ 2 L/min with sevoflurane to minimize Compound A accumulation in the circuit, particularly for lengthy procedures
• Baralyme produces more Compound A than Drägersorb or soda lime; Baralyme has largely been withdrawn from use

— [Morgan], p. 1238; [Barash], p. 3961

---

— [Barash], pp. 3600–3601

---

SECTION F: NITROUS OXIDE — SPECIAL CONSIDERATIONS

---

— [Miller], pp. 2044–2045 (references); [Barash], pp. 3961–3962

---

SECTION G: RAPID-FIRE HIGH-YIELD Q&A TABLE

---

---

SECTION H: SCENARIO-BASED QUESTIONS

---

1. Reactive airway disease: Sevoflurane bronchodilates effectively (> isoflurane) by reducing airway smooth muscle Ca²⁺ via IP₃/ryanodine receptor and GABA-A mediated mechanisms. It is non-pungent and does not provoke bronchospasm on induction. Desflurane is absolutely avoided.
2. Prior halothane hepatitis concern: Sevoflurane does not produce TFA intermediates or fluoroacetylated hepatic proteins (unlike isoflurane, desflurane, and halothane). It produces fluoride + HFIP, which are conjugated and renally excreted without hepatic immune sensitisation. It is considered the safest volatile for patients with prior halogenated agent reactions.

— [Barash], pp. 3961–3962

---

• Volatile agents inhibit HPV by approximately 20% at 1 MAC — translating to only a ~4% increase in Q̇s/Q̇t (intrapulmonary shunt)
• Multiple studies comparing isoflurane, sevoflurane, desflurane vs. propofol TIVA during OLV show no clinically significant difference in shunt fraction or PaO₂
• When anaesthetic depth is equalised by BIS monitoring, propofol and sevoflurane produce comparable reductions in oxygenation
• The key study (Murray, with chronically instrumented dogs) showed sevoflurane and desflurane preserved HPV as well as the conscious state

1. Apply CPAP (5 cmH₂O) to the non-dependent/non-ventilated lung
2. PEEP to the dependent (ventilated) lung
3. Intermittent two-lung ventilation
4. Surgical manipulation — clamping the pulmonary artery to the operative lung
5. Ensure adequate cardiac output (high CO removes more O₂ per cycle)

— [Miller], pp. 2113–2116

---

• N₂O is 34× more soluble in blood than nitrogen
• At the end of N₂O anaesthesia, large volumes of N₂O rapidly diffuse from blood into alveoli (outward flux)
• This outpouring of N₂O dilutes alveolar O₂ and CO₂
• The transient fall in PaO₂ → SpO₂ drop
• The reduced PETCO₂ may also blunt ventilatory drive, worsening hypoventilation

• Administer 100% O₂ for 3–5 minutes at the end of all N₂O anaesthetics before removing the mask/extubating
• This flushes N₂O from the alveoli and prevents dilutional hypoxaemia
• Ensure adequate ventilation during emergence to prevent additive hypoventilation

— [Miller]; [Morgan], Ch. 8

---

• Miller's Anesthesia, 2-Volume Set, 10th Edition (9780323935920)
• Barash, Cullen, and Stoelting's Clinical Anesthesia, 9th Edition (9781975199074)
• Morgan and Mikhail's Clinical Anesthesiology, 7th Edition (9781260473797)This extended Q&A set covers 20 questions across 8 sections drawn directly from all three core anaesthesia texts. Here's a quick map of what's been covered:

---

Topics Covered

• Three determinants of Palv rise (ventilation, CO, solubility)
• Overpressure technique
• Right-to-left shunt effect on induction (soluble vs. insoluble)
• Concentration effect and second gas effect
• Dead space effects (COPD, PE)

• MAC-awake, MAC-BAR, MAC-intubation with values
• Full table of MAC modifiers (increases/decreases)
• Anaemia and altered induction speed

• Agent-specific CVS profiles (halothane vs. iso vs. sevo vs. des)
• Desflurane sympathetic activation on rapid increase
• Anaesthetic preconditioning / myocardial protection

• Hypercapnic and hypoxic ventilatory response suppression (with MAC thresholds)
• HPV and one-lung ventilation evidence
• EEG signature of volatiles vs. propofol

• Halothane hepatitis mechanism and TFA metabolism comparison table
• Renal effects; Compound A controversy
• Paediatric agent selection (Barash)

• Contraindications and mechanisms
• Diffusion hypoxia / ENIGMA trials